
Sources have told Bloomberg News that Novo Holdings is currently investigating its options for a possible sale of Xellia Pharmaceuticals, which is headquartered in Amager, Copenhagen.
Advisors have been tasked with evaluating the case, which could generate at least USD 1bn (DKK 6.3bn), according to sources.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app